Business
Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update
Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity
About this update from Roivant Sciences Ltd.
[{"type":"text","content":"Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in 25 years; product and samples are now available across the US, a robust patient support program is in place and a 100+ person commercial organization is fully deployed to target 4 million potential annual topical psoriasis prescriptions in the USEnrollment in the VTAMA registrational trials for atopic dermatitis is ongoing, with data expected in the first half of calendar year 2023; represents significant expansion opportunity to target 15 million potential annual topical atopic dermatitis prescriptions in the US Priovant established in partnership with Pfizer to develop brepocitinib, a potential first-in-class dual, selective inhibitor of TYK2 and JAK1, for multiple orphan and specialty autoimmune diseases, including a recently initiated single potentially registrational Phase 3 trial in dermatomyositis and an ongoing potentially registrational trial in systemic lupus erythematosus (SLE) Ten or more pivotal or pivotal-enabling trials expected to be ongoing by the end of calendar year 2022, with seven already initiated Roivant reported $2.1B in cash and cash equivalents and reprioritized pipeline to focus on most meaningful opportunities while maintaining the financial flexibility to opportunistically in-license assets Early discovery efforts validated with announcement of multiple collaborations with Blueprint Medicines, Janssen and Boehringer Ingelheim that include aggregate contingent milestone payments of over $1 billion and product royalties Roivant appointed Melissa Epperly, a senior financial executive with extensive experience in the life sciences industry, to its Board of Directors, to begin serving concurrent with the planned departure of Pat Machado BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the fourth quarter and fiscal year ended March 31, 2022 and provided an update on the Company’s operations. Roivant’s Chief Executive Officer, Matt Gline, noted: “We are thrilled by the FDA approval of VTAMA for the ...